An analysis of the newly launched prediction platforms indicates that wagering on drug approvals is highly correlated with day traders actively praying for severe adverse events. However, investigators warn that it is too early to prove a causal link between shorting a therapeutic and sending hate mail to cured patients.
The findings, detailed in a recent JAMA paper, examined a cohort of Polymarket and Kalshi users who had wagered significant capital against the regulatory approval of several novel therapeutics. The routine for these bettors appeared to involve obsessively refreshing trial endpoints while hoping for elevated mortality rates in the active arm, though authors noted the sample size was entirely composed of amateur day traders.
When a promising oncology therapeutic demonstrated a clinically meaningful 40 percent reduction in tumor size during a double-blind trial last month, investigators observed a corresponding 85 percent spike in acute financial distress among Kalshi users holding "No" shares. While the patients experienced remission, the bettors suffered what researchers tentatively classified as severe secondary portfolio toxicity.
While early observations suggest these prediction markets incentivize users to aggressively root against the eradication of human disease, we must remember this is merely an observational study.
Federal regulators have issued preliminary recommendations cautioning that engaging with these markets could exacerbate sociopathic tendencies, though they acknowledged that shorting a cure for cystic fibrosis has not yet been definitively proven to cause clinical harm to the bettor. Representatives for Kalshi stated the platform simply provides liquidity, but confirmed they are considering a mandatory warning label advising users to consult a physician before betting their life savings on a placebo effect.
At press time, medical ethicists cautioned against drawing definitive conclusions after a group of Polymarket whales successfully lobbied the FDA to halt a promising Alzheimer’s trial, noting the correlation with their expiring options contracts could be entirely coincidental.